Zymeworks Inc. Share Price & Technical Analysis
ZYME · $25.61 (+1.99%)
Healthcare / Biotechnology
$25.61
+1.99%
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platfo…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-7% return in May, -5% avg return in past 3 year May month.
4% return in 2026, 57% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 4% | 11% | 10% | -7% | – | – | – | – | – | – | – | 4% |
| 25 | -1% | -6% | -11% | 10% | -12% | 10% | 2% | 19% | 23% | 12% | 41% | -1% | 87% |
| 24 | 5% | 10% | -13% | -18% | -1% | -1% | 24% | 11% | 9% | 9% | 10% | 3% | 47% |
| 23 | 19% | -14% | 10% | -7% | -2% | 5% | -13% | -4% | -12% | 11% | 27% | 18% | 38% |
| 22 | -46% | -20% | -10% | -8% | 8% | -22% | 9% | 12% | -3% | 21% | 5% | 1% | -51% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Uptrend · Uptrend
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.75B
P/E ratio
—
52W high
$29.75
52W low
$11.02
Volume
4,77,952
Beta
1.19
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Zymeworks Inc. share price today?
- Zymeworks Inc. (ZYME) last traded around $25.61 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ZYME have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ZYME. Download the app for real-time alerts.
- How can I analyze Zymeworks Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.